Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 147 articles: HTML format

Single Articles

September 2020
1. CARAM MEV, Oerline MK, Dusetzina S, Herrel LA, et al
   Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
   Cancer. 2020 Sep 14. doi: 10.1002/cncr.33176.
   PubMed     Abstract available
   
   
   
2. WEN W, Luckenbaugh AN, Bayley CE, Penson DF, et al
   Racial disparities in mortality for patients with prostate cancer after radical prostatectomy.
   Cancer. 2020 Sep 8. doi: 10.1002/cncr.33152.
   PubMed     Abstract available
   
   
   
3. KIM IE JR, Jang TL, Kim S, Modi PK, et al
   Abrogation of survival disparity between black and white individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
   Cancer. 2020 Sep 5. doi: 10.1002/cncr.33179.
   PubMed     Abstract available
   
   
   
4. PRINTZ C
   Prostate cancer mortality projections reach a new high: With prostate cancer deaths projected to rise to their highest level in 20 years, some experts worry that changes to screening guidelines made in 2012 could be a factor.
   Cancer. 2020;126:3893-3894.
   PubMed    
   
   
   July 2020
5. XU X, Fallah M, Tian Y, Mukama T, et al
   Risk of invasive prostate cancer and prostate cancer death in relatives of patients with prostatic borderline or in situ neoplasia: A nationwide cohort study.
   Cancer. 2020 Jul 22. doi: 10.1002/cncr.33096.
   PubMed     Abstract available
   
   
   
6. RIVIERE PJ, Rose BS
   Reply to Access and socioeconomic status play an important role in outcomes for African American patients with prostate cancer and Equal access to health care reduces racial disparities in prostate cancer outcomes.
   Cancer. 2020 Jul 9. doi: 10.1002/cncr.33064.
   PubMed    
   
   
   
7. LUNDON DJ, Dovey Z, Tewari AK
   Access and socioeconomic status play an important role in outcomes for African American patients with prostate cancer.
   Cancer. 2020 Jul 9. doi: 10.1002/cncr.33063.
   PubMed    
   
   
   
8. HOGE CG, Sussman J, Sidana A
   Equal access to health care reduces racial disparities in prostate cancer outcomes.
   Cancer. 2020 Jul 9. doi: 10.1002/cncr.33065.
   PubMed    
   
   
   June 2020
9. ITO K, Kobayashi M, Komiyama M, Naito S, et al
   Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
   Cancer. 2020 Jun 23. doi: 10.1002/cncr.33034.
   PubMed     Abstract available
   
   
   
10. VIDAL AC, Oyekunle T, Howard LE, De Hoedt AM, et al
    Obesity, race, and long-term prostate cancer outcomes.
    Cancer. 2020 Jun 4. doi: 10.1002/cncr.32906.
    PubMed     Abstract available
    
    
    
11. PRINTZ C
    First person profile: Maha Hussain, MD: Dr. Hussain's contributions to research on prostate cancer have led to major treatment advances.
    Cancer. 2020;126:2507-2508.
    PubMed    
    
    
    May 2020
12. PATEL DN, Howard LE, De Hoedt AM, Amling CL, et al
    Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
    Cancer. 2020 May 6. doi: 10.1002/cncr.32933.
    PubMed     Abstract available
    
    
    April 2020
13. WEINER AB, Vo AX, Desai AS, Hu JC, et al
    Changes in prostate-specific antigen at the time of prostate cancer diagnosis after medicaid expansion in young men.
    Cancer. 2020 Apr 28. doi: 10.1002/cncr.32930.
    PubMed     Abstract available
    
    
    
14. DALL'ERA MA, McPherson JD, Gao AC, DeVere White RW, et al
    Germline and somatic DNA repair gene alterations in prostate cancer.
    Cancer. 2020 Apr 21. doi: 10.1002/cncr.32908.
    PubMed     Abstract available
    
    
    March 2020
15. PRINTZ C
    Men who use assistive reproduction appear to have higher prostate cancer risk.
    Cancer. 2020;126:1148-1149.
    PubMed    
    
    
    
16. TANG C, Hoffman K, Kuban D
    Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancer.
    Cancer. 2020 Mar 11. doi: 10.1002/cncr.32840.
    PubMed    
    
    
    
17. HOGE C, Sidana A
    Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancer.
    Cancer. 2020 Mar 11. doi: 10.1002/cncr.32841.
    PubMed    
    
    
    February 2020
18. BUTLER SS, Dee EC, Lamba N, Sha ST, et al
    Validation of a subclassification for high-risk prostate cancer in a prospective cohort.
    Cancer. 2020 Feb 19. doi: 10.1002/cncr.32778.
    PubMed     Abstract available
    
    
    
19. LEHRER S, Rheinstein PH
    The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age.
    Cancer. 2020 Feb 19. doi: 10.1002/cncr.32788.
    PubMed    
    
    
    
20. HUYNH-LE MP, Seibert TM
    Reply to The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age.
    Cancer. 2020 Feb 19. doi: 10.1002/cncr.32791.
    PubMed    
    
    
    
21. JOSHI SS, Filson CP
    Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
    Cancer. 2020;126:694-696.
    PubMed    
    
    
    
22. SU ZT, Patel HD, Epstein JI, Pavlovich CP, et al
    Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
    Cancer. 2020 Feb 7. doi: 10.1002/cncr.32709.
    PubMed     Abstract available
    
    
    
23. BUTLER SS, Mahal BA
    Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself.
    Cancer. 2020 Feb 5. doi: 10.1002/cncr.32758.
    PubMed    
    
    
    
24. JOSHI SS, Filson CP
    Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself.
    Cancer. 2020 Feb 5. doi: 10.1002/cncr.32759.
    PubMed    
    
    
    
25. LEHRER SP
    Obesity and aggressive prostate cancer.
    Cancer. 2020 Feb 5. doi: 10.1002/cncr.32761.
    PubMed    
    
    
    
26. LYNCH SM, Sorice K, Tagai EK, Handorf EA, et al
    Use of empiric methods to inform prostate cancer health disparities: Comparison of neighborhood-wide association study "hits" in black and white men.
    Cancer. 2020 Feb 3. doi: 10.1002/cncr.32734.
    PubMed     Abstract available
    
    
    
27. ZHAI Z, Zheng Y, Li N, Deng Y, et al
    Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017.
    Cancer. 2020 Feb 3. doi: 10.1002/cncr.32733.
    PubMed     Abstract available
    
    
    January 2020
28. RIVIERE P, Luterstein E, Kumar A, Vitzthum LK, et al
    Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system.
    Cancer. 2020 Jan 27. doi: 10.1002/cncr.32666.
    PubMed     Abstract available
    
    
    
29. RODIN D, Chien AT, Ellimoottil C, Nguyen PL, et al
    Physician and facility drivers of spending variation in locoregional prostate cancer.
    Cancer. 2020 Jan 24. doi: 10.1002/cncr.32719.
    PubMed     Abstract available
    
    
    
30. MAHAL BA, Alshalalfa M, Zhao SG, Beltran H, et al
    Genomic and clinical characterization of stromal infiltration markers in prostate cancer.
    Cancer. 2020 Jan 6. doi: 10.1002/cncr.32688.
    PubMed     Abstract available
    
    
    
31. HUYNH-LE MP, Myklebust TA, Feng CH, Karunamuni R, et al
    Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.
    Cancer. 2020 Jan 3. doi: 10.1002/cncr.32702.
    PubMed     Abstract available
    
    
    December 2019
32. BUTLER SS, Muralidhar V, Zhao SG, Sanford NN, et al
    Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
    Cancer. 2019 Dec 3. doi: 10.1002/cncr.32604.
    PubMed     Abstract available
    
    
    November 2019
33. BERNARD B, Burnett C, Sweeney CJ, Rider JR, et al
    Impact of age at diagnosis of de novo metastatic prostate cancer on survival.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32630.
    PubMed     Abstract available
    
    
    
34. TANG C, Hoffman KE, Allen PK, Gabel M, et al
    Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32570.
    PubMed     Abstract available
    
    
    
35. EGGENER SE
    Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32574.
    PubMed    
    
    
    October 2019
36. LANGE JM, Laviana AA, Penson DF, Lin DW, et al
    Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.
    Cancer. 2019 Oct 22. doi: 10.1002/cncr.32557.
    PubMed     Abstract available
    
    
    September 2019
37. BLEYER A, Spreafico F, Barr R
    Prostate cancer in young men: An emerging young adult and older adolescent challenge.
    Cancer. 2019 Sep 25. doi: 10.1002/cncr.32498.
    PubMed     Abstract available
    
    
    
38. SARTOR O
    Why is prostate cancer incidence rising in young men?
    Cancer. 2019 Sep 25. doi: 10.1002/cncr.32497.
    PubMed    
    
    
    
39. SANTOS PMG, Barsky AR, Hwang WT, Deville C, et al
    Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.
    Cancer. 2019 Sep 10. doi: 10.1002/cncr.32457.
    PubMed     Abstract available
    
    
    
40. HIGANO CS, Armstrong AJ, Sartor AO, Vogelzang NJ, et al
    Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
    Cancer. 2019 Sep 4. doi: 10.1002/cncr.32445.
    PubMed     Abstract available
    
    
    August 2019
41. BARZI A, Lara PN Jr, Tsao-Wei D, Yang D, et al
    Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.
    Cancer. 2019 Aug 9. doi: 10.1002/cncr.32290.
    PubMed     Abstract available
    
    
    
42. TABLAZON IL, Howard LE, De Hoedt AM, Aronson WJ, et al
    Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Cancer. 2019 Aug 7. doi: 10.1002/cncr.32414.
    PubMed     Abstract available
    
    
    July 2019
43. 
    Erratum: Zhen JT, Syed J, Nguyen KA, et al. Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer. 2018:124:3105-3117.
    Cancer. 2019;125:2325.
    PubMed    
    
    
    
44. PRINTZ C
    Protein may be linked to racial disparities in prostate cancer.
    Cancer. 2019;125:2147.
    PubMed    
    
    
    June 2019
45. FANG AM, Glaser ZA, Rais-Bahrami S
    Increasing the use of active surveillance for prostate cancer in younger men.
    Cancer. 2019 Jun 28. doi: 10.1002/cncr.32333.
    PubMed    
    
    
    
46. MAHAL AR, Butler S, Franco I, Muralidhar V, et al
    Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
    Cancer. 2019 Jun 28. doi: 10.1002/cncr.32332.
    PubMed     Abstract available
    
    
    
47. ERIM DO, Bensen JT, Mohler JL, Fontham ETH, et al
    Prevalence and predictors of probable depression in prostate cancer survivors.
    Cancer. 2019 Jun 27. doi: 10.1002/cncr.32338.
    PubMed     Abstract available
    
    
    
48. DICKERMAN BA, Torfadottir JE, Valdimarsdottir UA, Giovannucci E, et al
    Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study.
    Cancer. 2019 Jun 10. doi: 10.1002/cncr.32167.
    PubMed     Abstract available
    
    
    
49. SHIRAZIPOUR CH, Freedland SJ
    Obesity, visceral adiposity, and prostate cancer: What is the role of lifestyle interventions?
    Cancer. 2019 Jun 10. doi: 10.1002/cncr.32165.
    PubMed    
    
    
    
50. BEAUMONT JL, Butt Z, Li R, Cella D, et al
    Meaningful differences and validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data.
    Cancer. 2019;125:1877-1885.
    PubMed     Abstract available
    
    
    May 2019
51. BUTLER SS, Mahal BA, Lamba N, Mossanen M, et al
    Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
    Cancer. 2019 May 31. doi: 10.1002/cncr.32202.
    PubMed     Abstract available
    
    
    
52. VICTORSON D, Schalet BD, Kundu S, Helfand BT, et al
    Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety.
    Cancer. 2019 May 15. doi: 10.1002/cncr.32189.
    PubMed     Abstract available
    
    
    
53. PINSKY PF, Black A, Daugherty SE, Hoover R, et al
    Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Cancer. 2019 May 8. doi: 10.1002/cncr.32176.
    PubMed     Abstract available
    
    
    
54. PRINTZ C
    Some black men may have more aggressive prostate cancer than scoring indicates.
    Cancer. 2019;125:1398-1399.
    PubMed    
    
    
    
55. JOHNSON DC, Yang JJ, Kwan L, Barsa DE, et al
    Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection.
    Cancer. 2019 May 1. doi: 10.1002/cncr.32170.
    PubMed     Abstract available
    
    
    April 2019
56. NIK-AHD F, Howard LE, Eisenberg AT, Aronson WJ, et al
    Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.
    Cancer. 2019 Apr 29. doi: 10.1002/cncr.32141.
    PubMed     Abstract available
    
    
    
57. TAGAWA ST, Vallabhajosula S, Christos PJ, Jhanwar YS, et al
    Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32072.
    PubMed     Abstract available
    
    
    
58. BARATA PC, Sartor AO
    Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or...
    Cancer. 2019 Apr 1. doi: 10.1002/cncr.32039.
    PubMed     Abstract available
    
    
    March 2019
59. SAAD AM, Gad MM, Al-Husseini MJ, AlKhayat MA, et al
    Suicidal death within a year of a cancer diagnosis: A population-based study.
    Cancer. 2019;125:972-979.
    PubMed     Abstract available
    
    
    
60. JANG TL, Kim IY, Scardino PT, Eastham JA, et al
    Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
    Cancer. 2019 Mar 12. doi: 10.1002/cncr.32054.
    PubMed    
    
    
    
61. DE CICCO L
    Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
    Cancer. 2019 Mar 12. doi: 10.1002/cncr.32055.
    PubMed    
    
    
    February 2019
62. DEKA R, Rose BS, Bryant AK, Sarkar RR, et al
    Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.31982.
    PubMed     Abstract available
    
    
    
63. POLACEK LC, Nelson CJ
    Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy: A psychological perspective.
    Cancer. 2019 Feb 12. doi: 10.1002/cncr.31980.
    PubMed    
    
    
    
64. AGGARWAL AK, Sujenthiran A, Lewis D, Walker K, et al
    Impact of patient choice and hospital competition on patient outcomes after prostate cancer surgery: A national population-based study.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31987.
    PubMed     Abstract available
    
    
    
65. VIDAL AC, Howard LE, De Hoedt A, Kane CJ, et al
    Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
    Cancer. 2019;125:434-441.
    PubMed     Abstract available
    
    
    January 2019
66. GORDON BE, Basak R, Carpenter WR, Usinger D, et al
    Factors influencing prostate cancer treatment decisions for African American and white men.
    Cancer. 2019 Jan 29. doi: 10.1002/cncr.31932.
    PubMed     Abstract available
    
    
    
67. CORRIGAN KL, Wall KC, Bartlett JA, Suneja G, et al
    Cancer disparities in people with human immunodeficiency virus: A systematic review of screening for non-AIDS-defining malignancies.
    Cancer. 2019 Jan 15. doi: 10.1002/cncr.31838.
    PubMed     Abstract available
    
    
    
68. SONPAVDE G, Agarwal N, Pond GR, Nagy RJ, et al
    Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31959.
    PubMed     Abstract available
    
    
    
69. PRINTZ C
    Early-age drinkers more likely to have high-grade prostate cancer later.
    Cancer. 2019;125:11.
    PubMed    
    
    
    December 2018
70. HOGE C, George A, Sidana A
    Partial gland therapy for prostate cancer.
    Cancer. 2018 Dec 20. doi: 10.1002/cncr.31823.
    PubMed    
    
    
    
71. KING MT, Nguyen PL, D'Amico AV, Orio PF 3rd, et al
    Reply to Partial gland therapy for prostate cancer.
    Cancer. 2018 Dec 20. doi: 10.1002/cncr.31822.
    PubMed    
    
    
    
72. WHITE C, Nimeh T, Gazelle GS, Weinstein MC, et al
    A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31884.
    PubMed     Abstract available
    
    
    
73. FOSTER CC, Weichselbaum RR, Pitroda SP
    Oligometastatic prostate cancer: Reality or figment of imagination.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31860.
    PubMed     Abstract available
    
    
    
74. LI T, Franco-Villalobos C, Proskorovsky I, Sorensen SV, et al
    Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31847.
    PubMed     Abstract available
    
    
    
75. SMITH L, Ae Lee J, Mun J, Pakpahan R, et al
    Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study.
    Cancer. 2018 Dec 5. doi: 10.1002/cncr.31857.
    PubMed     Abstract available
    
    
    
76. SENEVIRATNE MG, Bozkurt S, Patel MI, Seto T, et al
    Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer.
    Cancer. 2018 Dec 4. doi: 10.1002/cncr.31895.
    PubMed     Abstract available
    
    
    November 2018
77. BORNO HT, Lichtensztajn DY, Gomez SL, Palmer NR, et al
    Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
    Cancer. 2018 Nov 16. doi: 10.1002/cncr.31826.
    PubMed     Abstract available
    
    
    
78. NEGOITA S, Mariotto A, Benard V, Kohler BA, et al
    Reply to Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics.
    Cancer. 2018 Nov 14. doi: 10.1002/cncr.31845.
    PubMed    
    
    
    
79. MCKAY RR, Werner L, Jacobus SJ, Jones A, et al
    A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
    Cancer. 2018 Nov 14. doi: 10.1002/cncr.31836.
    PubMed     Abstract available
    
    
    
80. CURRY SJ, Krist AH, Owens DK
    Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics.
    Cancer. 2018 Nov 14. doi: 10.1002/cncr.31846.
    PubMed    
    
    
    
81. SUNDI D, Tosoian JJ, Nyame YA, Alam R, et al
    Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31833.
    PubMed     Abstract available
    
    
    
82. RESNICK MJ, Graves AJ, Gambrel RJ, Thapa S, et al
    The association between medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening.
    Cancer. 2018 Nov 9. doi: 10.1002/cncr.31700.
    PubMed     Abstract available
    
    
    October 2018
83. PRINTZ C
    New drug option for men with aggressive prostate cancer.
    Cancer. 2018;124:3797.
    PubMed    
    
    
    September 2018
84. JANG TL, Patel N, Faiena I, Radadia KD, et al
    Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer.
    Cancer. 2018 Sep 25. doi: 10.1002/cncr.31726.
    PubMed     Abstract available
    
    
    
85. SKOLARUS TA, Caram ME, Chapman CH, Smith DC, et al
    Castration Remains Despite Decreasing Definitive Treatment of Localized Prostate Cancer in the Elderly: A Case for De-Implementation.
    Cancer. 2018 Sep 7. doi: 10.1002/cncr.31665.
    PubMed    
    
    
    July 2018
86. ALONGI F, Corradini S, Arcangeli S
    Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31626.
    PubMed    
    
    
    
87. DALL'ERA MA, Lo MJ, Chen JY, Cress R, et al
    Reply to Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31625.
    PubMed    
    
    
    
88. KING MT, Nguyen PL, Boldbaatar N, Tempany CM, et al
    Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31568.
    PubMed     Abstract available
    
    
    June 2018
89. PRINTZ C
    Combined therapies improve survival in aggressive prostate cancer.
    Cancer. 2018;124:2470.
    PubMed    
    
    
    
90. MODI PK, Kaufman SR, Borza T, Yan P, et al
    Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations.
    Cancer. 2018 Jun 15. doi: 10.1002/cncr.31573.
    PubMed     Abstract available
    
    
    May 2018
91. NEGOITA S, Feuer EJ, Mariotto A, Cronin KA, et al
    Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
    Cancer. 2018 May 22. doi: 10.1002/cncr.31549.
    PubMed     Abstract available
    
    
    
92. THOMPSON IM JR
    The pendulum swings back: Screening for prostate cancer in 2018.
    Cancer. 2018 May 22. doi: 10.1002/cncr.31555.
    PubMed    
    
    
    
93. KEARNS JT, Holt SK, Wright JL, Lin DW, et al
    PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Cancer. 2018 May 21. doi: 10.1002/cncr.31337.
    PubMed     Abstract available
    
    
    
94. FILSON CP
    Moving toward a more rational, evidence-based approach to PSA screening, diagnosis, and treatment of prostate cancer.
    Cancer. 2018 May 21. doi: 10.1002/cncr.31332.
    PubMed    
    
    
    
95. BRYANT AK, D'Amico AV, Nguyen PL, Einck JP, et al
    Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
    Cancer. 2018 May 4. doi: 10.1002/cncr.31400.
    PubMed     Abstract available
    
    
    
96. BRAWLEY OW
    Prostate cancer screening: And the pendulum swings.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31380.
    PubMed    
    
    
    
97. HELGSTRAND JT, Roder MA, Klemann N, Toft BG, et al
    Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31384.
    PubMed     Abstract available
    
    
    April 2018
98. ZHEN JT, Syed J, Nguyen KA, Leapman MS, et al
    Genetic testing for hereditary prostate cancer: Current status and limitations.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31316.
    PubMed     Abstract available
    
    
    
99. REEVE BB, Tan X, Chen RC, Usinger DS, et al
    Symptom and function profiles of men with localized prostate cancer.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31401.
    PubMed     Abstract available
    
    
    March 2018
100. GOLAN R, Bernstein AN, Gu X, Dinerman BA, et al
     Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.
     Cancer. 2018 Mar 26. doi: 10.1002/cncr.31297.
     PubMed     Abstract available
     
     
     
101. DALL'ERA MA, Lo MJ, Chen J, Cress R, et al
     Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
     Cancer. 2018 Mar 2. doi: 10.1002/cncr.31285.
     PubMed     Abstract available
     
     
     January 2018
102. KAUR D, Ulloa-Perez E, Gulati R, Etzioni R, et al
     Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
     Cancer. 2018 Jan 25. doi: 10.1002/cncr.31253.
     PubMed     Abstract available
     
     
     
103. MCHUGH DJ, Root JC, Nelson CJ, Morris MJ, et al
     Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?
     Cancer. 2018 Jan 16. doi: 10.1002/cncr.31153.
     PubMed     Abstract available
     
     
     
104. MCDUFF SGR, Chen MH, Renshaw AA, Loffredo MJ, et al
     Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.
     Cancer. 2018 Jan 16. doi: 10.1002/cncr.31217.
     PubMed     Abstract available
     
     
     
105. PRINTZ C
     Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others.
     Cancer. 2018;124:11-12.
     PubMed    
     
     
     December 2017
106. ATKINS KM, Chen MH, Wu J, Renshaw AA, et al
     Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
     Cancer. 2017 Dec 20. doi: 10.1002/cncr.31204.
     PubMed     Abstract available
     
     
     
107. SAILER V, Schiffman MH, Kossai M, Cyrta J, et al
     Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
     Cancer. 2017 Dec 19. doi: 10.1002/cncr.31173.
     PubMed     Abstract available
     
     
     
108. PAL SK, Patel J, He M, Foulk B, et al
     Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
     Cancer. 2017 Dec 19. doi: 10.1002/cncr.31161.
     PubMed     Abstract available
     
     
     
109. STEELE CB, Li J, Huang B, Weir HK, et al
     Prostate cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
     Cancer. 2017;123 Suppl 24:5160-5177.
     PubMed     Abstract available
     
     
     
110. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
     Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.
     Cancer. 2017 Dec 12. doi: 10.1002/cncr.31141.
     PubMed     Abstract available
     
     
     
111. ALBERTSEN PC
     Prostate cancer screening with prostate-specific antigen: Where are we going?
     Cancer. 2017 Dec 12. doi: 10.1002/cncr.31140.
     PubMed    
     
     
     
112. MAHAL BA, Chen YW, Sethi RV, Padilla OA, et al
     Travel distance and stereotactic body radiotherapy for localized prostate cancer.
     Cancer. 2017 Dec 12. doi: 10.1002/cncr.31190.
     PubMed     Abstract available
     
     
     
113. ALIBHAI SMH, Breunis H, Timilshina N, Hamidi MS, et al
     Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
     Cancer. 2017 Dec 6. doi: 10.1002/cncr.31171.
     PubMed     Abstract available
     
     
     November 2017
114. ALBISINNI S, Joniau S, Quackels T, De Coster G, et al
     Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium.
     Cancer. 2017;123:4139-4146.
     PubMed     Abstract available
     
     
     
115. FREEDLAND SJ, Vidal AC, Howard LE, Terris MK, et al
     Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
     Cancer. 2017;123:4199-4206.
     PubMed     Abstract available
     
     
     October 2017
116. MAHAL AR, Mahal BA, Nguyen PL, Yu JB, et al
     Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance.
     Cancer. 2017 Oct 30. doi: 10.1002/cncr.31106.
     PubMed     Abstract available
     
     
     
117. GONZALEZ BD, Small BJ, Cases MG, Williams NL, et al
     Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia.
     Cancer. 2017 Oct 26. doi: 10.1002/cncr.31024.
     PubMed     Abstract available
     
     
     
118. BORZA T, Kaufman SR, Yan P, Herrel LA, et al
     Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care.
     Cancer. 2017 Oct 20. doi: 10.1002/cncr.31081.
     PubMed     Abstract available
     
     
     
119. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
     Psychological distress associated with cancer screening: A systematic review.
     Cancer. 2017;123:3882-3894.
     PubMed     Abstract available
     
     
     
120. CAMPODONICO F, Grillo-Ruggeri F, Grimaldi A, Zanardi S, et al
     Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up.
     Cancer. 2017 Oct 4. doi: 10.1002/cncr.31054.
     PubMed    
     
     
     
121. HURWITZ LM, Cullen J
     Reply to Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow-up.
     Cancer. 2017 Oct 4. doi: 10.1002/cncr.31053.
     PubMed    
     
     
     September 2017
122. LOPPENBERG B, Friedlander DF, Krasnova A, Tam A, et al
     Variation in the use of active surveillance for low-risk prostate cancer.
     Cancer. 2017 Sep 13. doi: 10.1002/cncr.30983.
     PubMed     Abstract available
     
     
     August 2017
123. YANG DD, Mahal BA, Muralidhar V, Boldbaatar N, et al
     Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
     Cancer. 2017 Aug 22. doi: 10.1002/cncr.30948.
     PubMed     Abstract available
     
     
     
124. HOFFMAN RM, Volk RJ, Wolf AMD
     Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation.
     Cancer. 2017 Aug 22. doi: 10.1002/cncr.30941.
     PubMed    
     
     
     
125. PRINTZ C
     Active surveillance helps prostate cancer patients keep quality of life, findings show.
     Cancer. 2017;123:2997.
     PubMed    
     
     
     
126. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
     Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
     Cancer. 2017;123:3116-3124.
     PubMed     Abstract available
     
     
     
127. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
     County-level cumulative environmental quality associated with cancer incidence.
     Cancer. 2017;123:2901-2908.
     PubMed     Abstract available
     
     
     
128. GORE JL, du Plessis M, Santiago-Jimenez M, Yousefi K, et al
     Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.
     Cancer. 2017;123:2850-2859.
     PubMed     Abstract available
     
     
     July 2017
129. POLLACK CE, Armstrong KA, Mitra N, Chen X, et al
     A multidimensional view of racial differences in access to prostate cancer care.
     Cancer. 2017 Jul 20. doi: 10.1002/cncr.30894.
     PubMed     Abstract available
     
     
     
130. EBOT EM, Gerke T, Labbe DP, Sinnott JA, et al
     Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.
     Cancer. 2017 Jul 12. doi: 10.1002/cncr.30831.
     PubMed     Abstract available
     
     
     
131. HURWITZ LM, Cullen J, Kim DJ, Elsamanoudi S, et al
     Longitudinal regret after treatment for low- and intermediate-risk prostate cancer.
     Cancer. 2017 Jul 5. doi: 10.1002/cncr.30841.
     PubMed     Abstract available
     
     
     
132. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
     Early estimates of SEER cancer incidence, 2014.
     Cancer. 2017;123:2524-2534.
     PubMed     Abstract available
     
     
     June 2017
133. SCHULMAN AA, Howard LE, Tay KJ, Tsivian E, et al
     Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
     Cancer. 2017 Jun 29. doi: 10.1002/cncr.30844.
     PubMed     Abstract available
     
     
     
134. PILIE PG, Johnson AM, Hanson KL, Dayno ME, et al
     Germline genetic variants in men with prostate cancer and one or more additional cancers.
     Cancer. 2017 Jun 28. doi: 10.1002/cncr.30817.
     PubMed     Abstract available
     
     
     
135. POMERANTZ MM, Spisak S, Jia L, Cronin AM, et al
     The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
     Cancer. 2017 Jun 13. doi: 10.1002/cncr.30808.
     PubMed     Abstract available
     
     
     
136. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
     The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
     Cancer. 2017;123:1912-1924.
     PubMed     Abstract available
     
     
     May 2017
137. FRENDL DM, Olumi AF
     Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer.
     Cancer. 2017 May 23. doi: 10.1002/cncr.30779.
     PubMed    
     
     
     
138. LI TT, Shore ND, Mehra M, Todd MB, et al
     Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease.
     Cancer. 2017 May 23. doi: 10.1002/cncr.30784.
     PubMed     Abstract available
     
     
     
139. VETTERLEIN MW, Loppenberg B, Karabon P, Dalela D, et al
     Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
     Cancer. 2017 May 4. doi: 10.1002/cncr.30744.
     PubMed     Abstract available
     
     
     April 2017
140. WALLNER LP, Jacobsen SJ
     Prostate cancer in black men: Is it time for personalized screening approaches?
     Cancer. 2017 Apr 24. doi: 10.1002/cncr.30685.
     PubMed    
     
     
     
141. TSODIKOV A, Gulati R, de Carvalho TM, Heijnsdijk EAM, et al
     Is prostate cancer different in black men? Answers from 3 natural history models.
     Cancer. 2017 Apr 24. doi: 10.1002/cncr.30687.
     PubMed     Abstract available
     
     
     
142. LAYNE TM, Weinstein SJ, Graubard BI, Ma X, et al
     Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
     Cancer. 2017 Apr 3. doi: 10.1002/cncr.30634.
     PubMed     Abstract available
     
     
     March 2017
143. HURWITZ MD, Harris J, Sartor O, Xiao Y, et al
     Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
     Cancer. 2017 Mar 21. doi: 10.1002/cncr.30620.
     PubMed     Abstract available
     
     
     February 2017
144. ADAMO MP, Boten JA, Coyle LM, Cronin KA, et al
     Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
     Cancer. 2017;123:697-703.
     PubMed     Abstract available
     
     
     
145. GOKCE MI, Wang X, Frost J, Roberson P, et al
     Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men.
     Cancer. 2017;123:583-591.
     PubMed     Abstract available
     
     
     
146. WANG H, Hoda RS, Faquin W, Rossi ED, et al
     FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
     Cancer. 2017;125:91-103.
     PubMed     Abstract available
     
     
     January 2017
147. COLLINS GS, Le Manach Y
     Nomograms need to be presented in full.
     Cancer. 2017;123:177-178.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: